Docetaxel and Oxaliplatin as First-Line Therapy for Advanced Non-Small Cell Lung Cancer: A Phase II Trial

REFERENCES

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.
   PubMed Web of Science ®Google Scholar
• Pfister DG, Johnson DH, Azzoli CG, et al. American Soci-ety of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22: 330–53.
   PubMed Web of Science ®Google Scholar
• Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000; 355: 479–85.
   PubMed Web of Science ®Google Scholar
• Chemotherapy in non-small cell lung cancer: a meta-analy-sis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. Br Med J 1995; 311: 899–909.
   Google Scholar
• Rosell R, Gatzemeier U, Betbcher DC, et al. Phase III ran-domised trial comparing paclitaxel/carboplatin with pacli-taxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13: 1539–49.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III ran-domized trial comparing three platinum-based doublets in ad-vanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285–91.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8.
   PubMed Web of Science ®Google Scholar
• Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542–50.
   PubMed Web of Science ®Google Scholar
• Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsqua-mous non—small-cell lung cancer: AVAiL. J Clin Oncol 2009; 1227–1234.
   Google Scholar
• Monnet I, Brienza S, Hugret F, et al. Phase II study of ox-aliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Tho-raciques. Eur J Cancer 1998; 34: 1124–7.
   Google Scholar
• Monnet I, de CH, Soulie P, et al. Oxaliplatin plus vinorel-bine in advanced non-small-cell lung cancer: final results of a mul-ticenter phase II study. Ann Oncol 2002; 13: 103–7.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed com-bined with oxaliplatin or carboplatin as first-line treatment in ad-vanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005; 11: 690–6.
   PubMed Web of Science ®Google Scholar
• Franciosi V, Barbieri R, Aitini E, et al. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients. Lung Cancer 2003; 41: 101–6.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Novello S, De Marinis F, et al. Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for ad-vanced non-small-cell lung cancer. Br J Cancer 2005; 93: 29–34.
   PubMed Web of Science ®Google Scholar
• Winegarden JD, Mauer AM, Otterson GA, et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 915–20.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guide-lines to evaluate the response to treatment in solid tumors. Eu-ropean Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
   PubMed Web of Science ®Google Scholar
• Spiro SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004; 59: 828–36.
   PubMed Web of Science ®Google Scholar
• Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of random-ized controlled trials. Lung Cancer 2008; 59: 1–11.
   PubMed Web of Science ®Google Scholar
• Azzoli CG, Kris MG, Pfister DG: Cisplatin versus carbo-platin for patients with metastatic non-small-cell lung cancer—an old rivalry renewed. J Natl Cancer Inst 2007; 99: 828–9.
   PubMedGoogle Scholar
• Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus car-boplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analy-sis. J Natl Cancer Inst 2007; 99: 847–57.
   PubMed Web of Science ®Google Scholar
• Monnet I, Soulie P, de Cremoux H, et al. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2001; 19: 458–63.
   PubMed Web of Science ®Google Scholar
• Kakolyris S, Ziras N, Vamvakas L, et al. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer 2006; 54: 347–52.
   PubMed Web of Science ®Google Scholar
• Raez LE, Santos ES, Lopes G, et al. Efficacy and safety of oxaliplatin and docetaxel in patients with locally advanced and metastatic non-small-cell lung cancer (NSCLC). Lung Cancer 2006; 53: 347–53.
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus peme-trexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543–51.
   PubMed Web of Science ®Google Scholar
• Einhorn LH: First-line chemotherapy for non-small-cell lung cancer: is there a superior regimen based on histology? J Clin Oncol 2008; 26: 3485–6.
   Google Scholar